All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Effect of evolocumab or ezetimibe added to moderateor high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia the LAPLACE-2 randomized clinical trial

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F14%3A00059164" target="_blank" >RIV/00023001:_____/14:00059164 - isvavai.cz</a>

  • Result on the web

    <a href="http://jama.jamanetwork.com/article.aspx?articleid=1869210" target="_blank" >http://jama.jamanetwork.com/article.aspx?articleid=1869210</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1001/jama.2014.4030" target="_blank" >10.1001/jama.2014.4030</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Effect of evolocumab or ezetimibe added to moderateor high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia the LAPLACE-2 randomized clinical trial

  • Original language description

    IMPORTANCE In phase 2 studies, evolocumab, a fully human monoclonal antibody to PCSK9, reduced LDL-C levels in patients receiving statin therapy. OBJECTIVE To evaluate the efficacy and tolerability of evolocumab when used in combination with a moderate-vs high-intensity statin. CONCLUSIONS AND RELEVANCE In this 12-week trial conducted among patients with primary hypercholesterolemia and mixed dyslipidemia, evolocumab added to moderate-or high-intensity statin therapy resulted in additional LDL-C lowering. Further studies are needed to evaluate the longer-term clinical outcomes and safety of this approach for LDL-C lowering. DESIGN, SETTING, AND PATIENTS Phase 3, 12-week, randomized, double-blind, placebo-and ezetimibe-controlled study conducted betweenJanuary and December of 2013 in patients with primary hypercholesterolemia and mixed dyslipidemia at 198 sites in 17 countries

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FA - Cardiovascular diseases including cardio-surgery

  • OECD FORD branch

Result continuities

  • Project

  • Continuities

    N - Vyzkumna aktivita podporovana z neverejnych zdroju

Others

  • Publication year

    2014

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    JAMA

  • ISSN

    0098-7484

  • e-ISSN

  • Volume of the periodical

    311

  • Issue of the periodical within the volume

    18

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    13

  • Pages from-to

    1870-1882

  • UT code for WoS article

    000335798100019

  • EID of the result in the Scopus database